NCT02342574View on ClinicalTrials.gov

F901318 Multiple Ascending Dose Study

PHASE1CompletedINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Invasive Aspergillosis

Interventions

DRUG

F901318

Administration of active compound

DRUG

Placebo

Administration of placebo

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research, London

Sponsors

Lead Sponsor

F2G Biotech GmbH

All Listed Sponsors

collaborator

Hammersmith Medicines Research

OTHER

lead

F2G Biotech GmbH

INDUSTRY